The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-γ Agonist

Mingzhi Su †, Jiafu Cao †, Jin Huang, Sen Liu, Dong Soon Im, Jin-Wook Yoo * and Jee H. Jung *

College of Pharmacy, Pusan National University, Busan 609-735, Korea; sumingzhi0310@gmail.com (M.S.); caojiafu1985@163.com (J.C.); jellyohuang@gmail.com (J.H.); ls691392008@sina.com (S.L.);
imds@pusan.ac.kr (D.S.I.)
* Correspondence: jinwook@pusan.ac.kr (J.-W.Y.); jhjung@pusan.ac.kr (J.H.J.);
Tel.: +82-51-510-2807 (J.-W.Y.); +82-51-510-2803 (J.H.J.)
† These authors equally contributed to this work.

Abstract: Previously, the authors found that 4-hydroxy-2-(4-hydroxyphenethyl) isoindoline-1,3-dione (PD1) (a phthalimide analogue) bound to and activated peroxisome proliferator-activated receptor-γ (PPAR-γ). Since PPAR-γ suppresses inflammatory responses, the present study was undertaken to investigate the anti-inflammatory effects of PD1. In lipopolysaccharide (LPS)-stimulated murine RAW264.7 macrophages, PD1 suppressed the inductions of pro-inflammatory factors, including inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase 2 (COX-2), tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Concomitantly, PD1 enhanced the expressions of anti-inflammatory factors, such as arginase-1 and interleukin-10 (IL-10), and suppressed LPS-evoked nuclear factor kappa B (NF-κB) p65 subunit phosphorylation in macrophages. In addition, PPAR-γ activated by PD1 was intensively translocated to the nucleus. These observations suggest that the anti-inflammatory mechanism of PD1 involves inhibition of the NF-κB pathway. In a subsequent in vivo animal experiment conducted using a carrageenan-induced acute inflammatory rat paw edema model, intraperitoneal injection of PD1 significantly reduced paw swelling. Histological analysis of rat paw tissue sections revealed less infiltration of immune cells in PD1-pretreated animals. These findings suggest that PD1 be viewed as a lead compound for the development of novel anti-inflammatory therapeutics.

Keywords: anti-inflammatory effect; PPAR-γ agonist; phthalimide analogue; RAW264.7 macrophage; cytokines; NF-κB pathway; paw edema

1. Introduction

Peroxisome proliferator-activated receptor (PPAR)-γ is a member of the nuclear receptor superfamily, which are activated by ligands, such as endogenous 15-deoxy-Δ12,14-prostaglandin J2 and insulin-sensitizing thiazolidinediones [1]. Activated PPAR-γ translocates to the cell nucleus and binds to peroxisome proliferator response element (PPRE) on target DNA to regulate gene transcription. PPAR-γ is predominantly present in adipose tissue, colon, skeletal muscle, endothelium, macrophages, and monocytes, and plays important roles in the regulation of insulin sensitivity, lipid metabolism, adipogenesis, and glucose homeostasis [2]. PPAR-γ is also involved in the regulations of immune and inflammatory responses [3,4]. Many inflammatory diseases stem from the activation of macrophages, and it is known that classically activated M1 macrophages induced by infection, tissue damage, or exposure to endotoxins (i.e., lipopolysaccharide (LPS)) secrete large amounts of pro-inflammatory mediators, such as nitric oxide (NO), inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α), whereas
activated M2 macrophages secrete Transforming growth factor beta 1 (TGF-β1), IL-10, and arginase-1, and thus play important anti-inflammatory and tissue restorative roles. A recent study revealed that the anti-inflammatory effects of PPAR-γ are due to its modulation of macrophage activation, which is a prerequisite for the optimal induction of the M2 macrophage phenotype by interleukin-4 [4]. It is also known that PPAR-γ activation leads to the repression of pro-inflammatory genes, such as iNOS, COX-2, and IL-6, and inhibits the expressions of cytokines and acute phase proteins by inhibiting the nuclear factor kappa B (NF-κB) pathway [4–8].

Over the past decade, it has been demonstrated that PPAR-γ agonists are potentially beneficial for treating several inflammatory diseases. Rosiglitazone, which is used clinically to treat type II diabetes mellitus, has been reported to inhibit the expressions of inflammatory cytokines during LPS-induced acute kidney injury [9], and to have anti-inflammatory effects in carrageenan-induced paw edema and carrageenan-induced pleurisy [10]. In addition, rosiglitazone and other PPAR-γ agonists were found to be effective in a murine airway-inflammation model by reducing airway hyper-responsiveness and mucus production [11], and to suppress neutrophilia and chemoattractant production, thus inhibiting inflammatory response [12]. PPAR-γ agonists have also been reported to be effective in models of myocarditis and intestinal inflammation [13,14]. For example, pioglitazone and telmisartan both improved myocardial injury in diabetes by inhibiting receptor of advanced glycation end products (RAGE)-mediated oxidative stress and inflammation [15,16]. Furthermore, our group previously reported that a jasmonate analogue designed and synthesized as a PPAR-γ agonist exerted anti-inflammatory effects in murine colitis [17,18].

In a previous study, we isolated a new marine natural product paecilocin A (Figure 1A) from the jellyfish-derived fungus *Paecilomyces variotii* with good antibacterial activity [19]. In a subsequent screening for PPAR-γ competitive binding activity, synthetic paecilocin A analogues showed PPAR-γ binding activity comparable to that of rosiglitazone [20]. Thereafter, we designed and synthesized a series of N-substituted phthalimide analogues based on the pharmacophore study of paecilocin A and synthetic analogues. One of the N-substituted phthalimide analogues, 4-hydroxy-2-(4-hydroxyphenethyl) isoindoline-1,3-dione (PD1, Figure 1B), was found to exhibit significant PPAR-γ agonistic activity in Ac2F murine liver cells and in HepG2 human liver cells [21,22].

![Figure 1](image_url)

*Figure 1.* Chemical structures of paecilocin A (A) and PD1 (4-hydroxy-2-(4-hydroxyphenethyl) isoindoline-1,3-dione) (B).

In this study, we investigated the anti-inflammatory effects of PD1 using LPS-activated RAW264.7 murine macrophages. The productions of pro-inflammatory and anti-inflammatory mediators were examined at the cellular level, and an in vivo study was conducted to examine the anti-inflammatory activity of PD1 using a carrageenan-induced acute inflammatory paw edema model. In addition, we provide a discussion of the anti-inflammatory mechanism of PD1 in LPS-induced RAW264.7 macrophages.
2. Results and Discussion

2.1. PD1 Promoted PPAR-γ Translocation to Cell Nuclei

Prior to in vitro anti-inflammatory evaluation of PD1, the potential toxicity of PD1 was tested in human embryonic kidney cells (HEK293T), rat liver Ac2F cells, and RAW264.7 murine macrophages. PD1 was found to be non-cytotoxic to any of these cell lines after exposure to concentrations up to 50 μM for 24 h (Figure 2).

![Figure 2](image)

**Figure 2.** Cytotoxicity evaluation of PD1 (10, 25, or 50 μM) on human embryonic kidney cells (HEK293T), Ac2F rat liver cells, and RAW264.7 macrophages at 24 h.

After ligand binding, PPAR-γ translocates to the nucleus and modulates gene transcription and expression. In a previous study, the PPAR-γ agonistic activity of PD1 was examined by luciferase assay using PPRE-luciferase reporter plasmid [21,22]. In the present study, we assessed levels of PD1-activated PPAR-γ proteins translocated to the cell nuclei of RAW264.7 cells by Western blot. As shown in Figure 3, endonuclear PPAR-γ protein levels were significantly and concentration-dependently enhanced by PD1 treatment. PPAR-γ expressed in inflammatory cells can regulate metabolic and inflammatory processes [23]. Thus, we hypothesized that endonuclear PPAR-γ activated by PD1 could initiate a series of responses that regulate inflammatory and/or resolution processes.

![Figure 3](image)

**Figure 3.** Endonuclear peroxisome proliferator-activated receptor-γ (PPAR-γ) protein levels in RAW264.7 macrophages treated with PD1 for 24 h as determined by Western blotting. Nuclear levels of transcription Factor II B (TF II B) were used for reference purposes. The results shown are representative of three independent experiments. ## p < 0.01 vs. untreated controls.
2.2. Decreased Expression of Pro-Inflammatory Factors by PD1

In order to elucidate the role of the PD1 in inflammation, we examined the transcription levels of pro-inflammatory factors. Macrophages stimulated with LPS showed substantial increases in the levels of pro-inflammatory factors. To investigate the anti-inflammatory effect of PD1, the mRNA levels of specific genes, such as iNOS, COX-2, TNF-α, IL-1β, and IL-6 in RAW264.7 cells, were assessed using reverse transcriptase-PCR (RT-PCR). It was found that the mRNA levels of pro-inflammatory mediators were markedly increased when murine macrophages RAW264.7 were exposed to LPS for 1 h, and that these increases were significantly and concentration-dependently diminished by pre-treating cells with PD1 (Figure 4). Notably, at a concentration of 50 µM PD1 significantly inhibited the mRNA levels of iNOS, COX-2, TNF-α, IL-1β, and IL-6 to extents comparable to those of 10 µM dexamethasone.

Figure 4. Reverse transcriptase-PCR (RT-PCR) results of pro-inflammatory genes. RAW264.7 cells were pre-treated with the indicated concentrations of PD1 or dexamethasone (DEX) for 1 h, and then treated with lipopolysaccharide (LPS) (10 ng/mL, 1 h). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal reference. The results shown are representative of three independent experiments. **p < 0.01, ***p < 0.001 vs. untreated controls. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. LPS-treated cells.

In addition, the protein levels of the pro-inflammatory factors iNOS and COX-2 were analyzed by Western blot and enzyme-linked immunosorbent assay (ELISA). In LPS-induced RAW264.7 cells, both were inhibited by PD1 (Figure 5A). Since iNOS is a family of enzymes that catalyze NO production from L-arginine, we supposed reductions in iNOS expression by PD1 should lead to decreased NO production in macrophages, and thus we measured NO amounts in RAW264.7 cell supernatants using Griess reagent. NO levels were found to be significantly increased by LPS (Figure 5B), but these increases were significantly and concentration-dependently inhibited by PD1 pre-treatment. For example, after treatment with 50 µM PD1, LPS-induced NO increases were inhibited by 66%. Furthermore, PD1 pre-treatment reduced the LPS-induced secretions of TNF-α, IL-1β, and IL-6 (Figure 5C–E). This result is consistent with those of other studies, which reported that treatment of monocytes or macrophages with high concentrations of PPAR-γ agonists reduced the secretions of pro-inflammatory cytokines by inhibiting macrophage activation [10].
After stimulating RAW264.7 macrophages with LPS, the expression of arginase-1 decreased, the expressions of several pro-inflammatory factors, including interferon-γ (IFN-γ), IL-1β, IL-6, and TNF-α in macrophages and lymphocytes, and to inhibit the production of prostaglandin E2 (PGE2) by reducing COX-2 expression [27,28]. Yang et al. pointed out that the transcriptional activity of IL-10 is strongly related to PPAR-γ expression [29]. Furthermore, PPAR-γ agonists have been shown to induce IL-10 production and enhance protective effects in an asthma model [30]. Our results show PD1 exerts an anti-inflammatory effect by inhibiting the pro-inflammatory mediators (NO, iNOS, COX-2, IL-1β, IL-6, and TNF-α) and promoting the expressions of anti-inflammatory mediators (arginase-1 and IL-10) in RAW264.7 cells.

**Figure 5.** Effect of PD1 on the inductions and secretions of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) (A); nitric oxide (NO) (B); tumor necrosis factor α (TNF-α) (C); interleukin-1β (IL-1β) (D); and interleukin-6 (IL-6) (E). RAW264.7 macrophages were pre-treated with the indicated concentrations of PD1 or dexamethasone (DEX) for 1 h and then with LPS (1 μg/mL, 24 h), and iNOS and COX-2 levels were determined by Western blot. RAW264.7 macrophages were pre-treated with PD1 or dexamethasone (DEX) for 1 h and then with LPS (25 ng/mL, 24 h), and NO concentration in medium were determined by enzyme-linked immunosorbent assay (ELISA). In the case of TNF-α, cells were pre-treated with PD1 or dexamethasone for 1 h and then with LPS (25 ng/mL, 3 h). The results shown are representative of three independent experiments. **p < 0.01, *** p < 0.001 vs. untreated controls. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. LPS-treated cells.

2.3. **PD1 Enhanced the Expressions of Anti-Inflammatory Factors**

Both iNOS and arginase-1 are required for the metabolism of L-arginine. Arginase-1 affects inflammatory responses through L-arginine metabolism, which generates proline and polyamines, and ultimately enhances collagen synthesis, cell proliferation, tissue repair, and wound healing [24]. The anti-inflammatory factors arginase-1 was assessed in both mRNA (Figure 6A) and protein levels (Figure 6B). After stimulating RAW264.7 macrophages with LPS, the expression of arginase-1 decreased, but this reduction was almost totally recovered by PD1 pre-treatment. Gao et al. showed activation of the signal transducer and activator of transcription 6 (STAT6) signaling pathway promotes PPAR-γ and arginase-1 expressions simultaneously, and that PPAR-γ synergistically augments the expression of arginase-1 [25].

Furthermore, the transcriptional level of IL-10 was reduced by LPS treatment in RAW264.7 macrophages, and as was observed for arginase-1, this reduction was diminished by PD1 pre-treatment (Figure 6A). By attenuating the activations of immune cells, IL-10 acts as a potent antagonist of pro-inflammatory cytokines. The principal function of IL-10 appears to be the suppression and ultimately the termination of inflammatory responses [26]. In fact, IL-10 has the ability to suppress the expressions of several pro-inflammatory factors, including interferon-γ (IFN-γ), IL-1β, IL-6, and TNF-α in macrophages and lymphocytes, and to inhibit the production of prostaglandin E2 (PGE2) by reducing COX-2 expression [27,28]. Yang et al. pointed out that the transcriptional activity of IL-10 is strongly related to PPAR-γ expression [29]. Furthermore, PPAR-γ agonists have been shown to induce IL-10 production and enhance protective effects in an asthma model [30]. Our results show PD1 exerts an anti-inflammatory effect by inhibiting the pro-inflammatory mediators (NO, iNOS, COX-2, IL-1β, IL-6, and TNF-α) and promoting the expressions of anti-inflammatory mediators (arginase-1 and IL-10) in RAW264.7 cells.
To investigate the mechanism responsible for the effect of LPS on macrophages. However, some authors have suggested that PPAR-γ interferes with several transcription factors involved in pro-inflammatory signal pathways, such as activator protein-1 (AP-1), signal transducers and activators of transcription 1 (STAT-1), and nuclear factor of activated T cells (NFAT) [23]. However, others have shown that PPAR-γ suppresses the pro-inflammatory process by repressing NF-κB activity [5].

2.4. Modulation of the NF-κB Pathway by PD1

Some authors have suggested that PPAR-γ interferes with several transcription factors involved in pro-inflammatory signal pathways, such as activator protein-1 (AP-1), signal transducers and activators of transcription 1 (STAT-1), and nuclear factor of activated T cells (NFAT) [23]. However, others have shown that PPAR-γ suppresses the pro-inflammatory process by repressing NF-κB activity [5].

To investigate the mechanism responsible for the effect of PD1 on LPS-activated NF-κB signaling, we examined NF-κB p65 phosphorylation levels in RAW264.7 macrophages. As was expected, the protein levels of phosphorylated p65 subunits were significantly increased in cells after LPS (20 ng/mL) treatment for 15 min (Figure 7), indicating that LPS exposure promotes activation of the NF-κB pathway. However, PD1 pre-treatment significantly reduced NF-κB p65 phosphorylation with a potency comparable to that of dexamethasone at the same concentration (50 μM). It was previously supposed PPAR-γ might antagonize NF-κB activity via some protein–protein interaction [10,18].

Our findings suggest that PD1 inhibits the inflammatory process by suppressing the NF-κB pathway.
Figure 7. Phosphorylated nuclear factor kappa B (NF-κB) p65 levels in RAW264.7 murine macrophages were determined by Western blot using β-actin as the internal control. Cells were pretreated with PD1 (50 μM) or dexamethasone (DEX, 50 μM) for 30 min, and stimulated with 20 ng/mL LPS for 15 min. *** p < 0.001 vs. untreated controls. * p < 0.05 and ** p < 0.01 vs. LPS-treated cells.

2.5. Anti-Inflammatory Effect of PD1 in a Carrageenan-Induced Paw Edema Model

The anti-inflammatory effects of PD1 were evaluated in vivo using a carrageenan-induced paw edema model, as previously described [31]. Injection of 1% carrageenan phosphate buffered saline (PBS) solution 0.1 mL into a hind paw of Wistar rats resulted in edema, which was assessed by measuring paw thicknesses (Figure 8). Carrageenan was found to have a maximum effect at 2 h after injection when 37.8% paw thickening was observed. Swelling was sustained for 3 h and slowly decreased to 29.9% at 6 h post-injection. Intraperitoneal injection of PD1 (50 mg/kg) 1 h before carrageenan injection suppressed paw edema. The mean paw thickening was 40.1% in 1 h, 35.7% at 2 h, 29.6% at 3 h, and 22.6% at 6 h. This suppressive efficacy of PD1 was comparable to that of diclofenac (20 mg/kg), but lower than that of dexamethasone (20 mg/kg).

Figure 8. Changes in the paw thicknesses (mm) of Wistar rats. Photographs showing a representative paw before (A) and after (B) carrageenan injection. Changes in paw thickness after pre-treatment with PD1, dexamethasone, or diclofenac (50, 20, and 20 mg/kg, respectively) (C). Results are presented as means ± SDs of n = 6 rats/group. Control: phosphate buffered saline (PBS)-injected; Carrageenan: carrageenan-injected; PD1: PD1-pretreated; Dexamethasone: dexamethasone-pretreated; Diclofenac: diclofenac-pretreated.
Microscopic photographs of hematoxylin and eosin stained normal paw tissue are shown in Figure 9A. High levels of infiltration-related damage, due to accumulations of immune cells and fluid collection, were observed in carrageenan-treated rats (arrowed in Figure 9B). However, PD1 (Figure 9C), dexamethasone (Figure 9D), and diclofenac pretreated (Figure 9E) rats showed only moderate infiltration damage. The anti-inflammatory effect of PD1 pretreatment was comparable to that of the positive controls dexamethasone and diclofenac. Notable dermal thickening was also observed in carrageenan-treated rats due to fluid collection. Quantitative analysis of dermal thicknesses showed that the dermises of carrageenan treated animals were significantly thickened by fluid infiltration (Figure 9F). PD1, dexamethasone, and diclofenac pretreated animals showed similar reductions in carrageenan-induced thickening.

**Figure 9.** Histological examination of paw tissue sections 3 h after carrageenan injection. (A) normal control; (B) carrageenan control; and after (C) pretreatment with PD1; (D) dexamethasone; or (E) diclofenac. High levels of accumulations of immune cells and fluid collection were observed in carrageenan-treated rats (arrowed in B); (F) dermal thicknesses were measured in a quantitative manner using a caliper. Control (CON), PBS-injected; non-treatment (NT), carrageenan-injected; PD1, PD1-pretreated; DIC, diclofenac-pretreated; DEX, dexamethasone-pretreated. *p < 0.05 and **p < 0.01 vs. NT. Scale bar: 100 μm.

Cytokines TNF-α, IL-1β, and IL-6 are small regulatory proteins produced by activated immune cells that associate with cellular injuries and signs of inflammation and contribute to fever, acute phase protein release, vascular permeability, and inflammatory cell recruitment [32]. Considering the importance of the role played by cytokines in inflammatory response, we evaluated the effect of PD1 in a carrageenan-induced acute inflammation model to assess the effect of the PPAR-γ agonist PD1. Inflammatory symptoms as assessed by paw thicknesses, tissue damage, fluid collection, and immune cell infiltration were found to be alleviated by PD1. These findings indicate the anti-inflammatory effects of PD1 are due to its ability to reduce the productions of pro-inflammatory mediators.

3. Materials and Methods

3.1. Materials

Phthalimide analogue PD1, 4-hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione, was synthesized by our group [21]. Dimethylsulfoxide (DMSO), diclofenac, dexamethasone,
lipopolysaccharide, Griess reagent, and carrageenan were purchased from Sigma-Aldrich (St. Louis, MO, USA). Primers for RT-PCR experiment were synthesized by BIONEER (Daejeon, Korea).

3.2. Cell Culture and Cell Viability

RAW264.7 murine macrophages were purchased from the Korean Cell Line Bank (KCLB®, Seoul, Korea), and rat liver Ac2F cells and human embryonic kidney 293T cells (HEK 293T) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured at 37°C in a 5% CO₂ humidified incubator and maintained in high glucose Dulbecco’s Modified Eagle Medium (DMEM, Nissui, Tokyo, Japan) containing 100 mg/mL streptomycin, 2.5 mg/L amphotericin B and 10% heat-inactivated fetal bovine serum (FBS). Cells were seeded in a 96-well culture plates and cultured for 12 h and then treated with various concentrations of PD1 for 24 h. Cell viabilities were evaluated using water soluble tetrazolium (WST) reagent (EZ-CyTox, Daeil Lab Service Co., Ltd., Seoul, Korea), which was added to each well (10 µL) and incubated at 37°C for 1 h. Absorbances were read using a iMark Microplate Absorbance Reader (Bio-Rad Laboratories, Hercules, CA, USA) at a wavelength of 450 nm.

3.3. Reverse Transcriptase-PCR (RT-PCR)

To determine the expressions of inflammatory markers in RAW264.7 cells by RT-PCR, total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and first strand cDNA was synthesized using total RNA and the M-MLV cDNA Synthesis kit (Enzynomics, Daejeon, Korea). cDNA products and primers for each gene were used for PCR with AccuPower® PCR PreMix (BIONEER, Seoul, Korea) in a BIO-RAD T100™ Thermal Cycler PCR unit (Hercules, CA, USA). Specific primers for iNOS (sense 5′-ACC TAC CAC ACC CGA GAT GGC CAG-3′, antisense 5′-AGG ATG TCC TGA ACA TAG ACC TTG GG-3′), COX-2 (sense 5′-CCG TGG GGA ATG TAT GAG CA-3′, antisense 5′-CCA GGT CCT CGC TTA TGA TCT G-3′), TNF-α (sense 5′-AGCACAGAAGCATGGTCCG-3′, antisense 5′-GTTTGTACGACGGCTGCA-3′), IL-1β (sense 5′-GGA GAA GCT GTG GCA GCT A-3′, antisense 5′-GGT GAT GTA CCA GTT GG-3′), IL-6 (sense 5′-TGG GAA ATCGTG GAA ATG AG-3′, antisense 5′-GAA GGA CTC TGG CTT GTG GA-3′), and GAPDH (sense 5′-TTC ACC ACC ATG GAG AAG GC-3′, antisense 5′-GGC ATG GAC TGT GGT CAT GA-3′) were used to amplify gene fragments. PCR was performed over 24 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 30 s. Arginase-1 (sense 5′-GTG AAG AAC CCA CGG TCT GT-3′, antisense 5′-CCG TGT GTT GTC GGG GAG TGT T-3′) and GAPDH (sense 5′-TTC ACC ACC ATG GAG AAG GC-3′, antisense 5′-GGC ATG GAC TGT GGT CAT GA-3′) were used to amplify gene fragments. PCR was performed over 24 cycles of denaturation at 95°C for 30 s and annealing at 55°C for 30 s. Aliquots (6 µL) were electrophoresed in 1.2% agarose gels and stained with ethidium bromide [33].

3.4. Western Blot

Cells were harvested and suspended in lysis buffer containing protease and phosphatase inhibitor cocktails. Nuclear protein extraction was performed using NE-PER® nuclear and cytoplasmic extraction reagents (Thermo Scientific, Rockford, IL, USA). Concentrations of proteins were determined using a BCA protein assay (Thermo Scientific, Rockford, IL, USA). Equal amounts of proteins were resolved by 8% SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes, which were then blocked in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and 5% skimmed milk for 1 h at room temperature, and then incubated with specific primary antibodies recognizing COX-2, iNOS, arginase -1, PPAR-γ, and NF-κB p-p65 (Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C. Anti-rabbit horseradish-linked IgG was used as the secondary antibody. Signals were developed using the ChemiDoc™ Touch Imaging System (Bio-Rad Laboratories, Hercules, CA, USA).
3.5. Production Levels of NO and Cytokines

RAW264.7 macrophages (1 × 10^4 cells/well) were seeded in a 96-well culture plate and cultured for 12 h. Cells were pre-treated with various concentrations of PD1 or dexamethasone for 1 h and then co-incubated with 25 ng/mL of LPS for 24 h. NO concentrations in medium were determined using a Griess assay. Griess reagent (80 µL) was added to media supernatants (80 µL) and then incubated at 37 °C for 15 min in the dark. Absorbance was measured at 520 nm. NO concentrations were calculated using 0–100 µM sodium nitrite standards. TNF-α, IL-1β, and IL-6 expression levels in culture medium were quantified using a sandwich-type ELISA kits (Biolegend, San Diego, CA, USA).

3.6. Animals

Male Wistar rats (130–150 g, 5-weeks old) were purchased from Daehan Biolink (DBL, Seoul, Korea) and housed under standard laboratory conditions (22 °C ± 2 °C under a 12 h light/dark schedule) with free access to food and water. Prior to use, animals were allowed 1 week to acclimatize. The animal protocol used in this study was reviewed and approved beforehand by the Pusan National University–Institutional Animal Care and Use Committee (PNU–IACUC) with respect to the ethicality of procedures and animal care.

3.7. Carrageenan-Induced Rat Paw Edema Assay

The carrageenan-induced hind paw edema was used to assess anti-inflammatory activity, as previously described [31]. Animals were divided into four groups (n = 6/group, three of which were used for histological analysis). PD1 (50 mg/kg), dexamethasone (20 mg/kg), and diclofenac (20 mg/kg) were dissolved in PBS containing 10% DMSO and administered once by intraperitoneal injection. Vehicle controls were injected with vehicle alone. Thirty minutes post-injection, paw edema was induced by a subplantar injection of 0.1 mL of 1% freshly prepared carrageenan suspension in PBS into the left hind paw of each rat. Right hind paws were injected with 0.1 mL of PBS. To gauge the extents of inflammation, paw thicknesses were measured before (0 h) and at 1, 2, 3, 4, and 6 h after carrageenan injection using a digital vernier caliper (Mitotoyu, Series 500, Tokyo, Japan).

3.8. Histology

Three animals from each group were euthanized 3 h after carrageenan injection. Paw samples were taken for histological examination. Sectioned tissues were stained with hematoxylin and eosin and viewed under bright field microscope (OLYMPUS, BX53F, Tokyo, Japan).

3.9. Statistics

The significances of intergroup differences were determined by ANOVA. Results are expressed as the means ± SDs of indicated numbers of independent experiments. Statistical significance was accepted for p-values of < 0.05.

4. Conclusions

The present study shows that the PPAR-γ agonist PD1 has substantial in vitro and in vivo anti-inflammatory activities. The mechanism underlying these anti-inflammatory effects appears to involve the activation of PPAR-γ and the suppression of NF-κB. In turn, the activation of PPAR-γ by PD1 reduced the expressions of pro-inflammatory mediators, that is, iNOS, NO, COX-2, TNF-α, IL-1β, and IL-6, by inhibiting NF-κB, and concomitantly increased the expressions of anti-inflammatory mediators, such as arginase-1 and IL-10. Furthermore, in our rat paw edema model, PD1 substantially reduced acute inflammation and attenuated immune cell infiltration. These findings demonstrate that PD1 has potential use as a lead compound by those developing therapeutic agents for the treatment of acute inflammation.
Acknowledgments: This research was a part of a project entitled “Omics based fishery disease control technology development and industrialization” funded by the Korean Ministry of Oceans and Fisheries.

Author Contributions: Mingzhi Su, Jiafu Cao and Jin Huang conceived and designed the experiments; Mingzhi Su and Jiafu Cao performed the experiments; Mingzhi Su and Jiafu Cao analyzed the data; Sen Liu contributed materials; Mingzhi Su, Jiafu Cao, Dong Soon Im, Jin-Wook Yoo and Jee H. Jung wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kliewer, S.A.; Xu, H.E.; Lambert, M.H.; Willson, T.M. Peroxisome proliferator-activated receptors: From genes to physiology. Recent Prog. Horm. Res. 2000, 56, 239–263. [CrossRef] [PubMed]
2. Spiegelman, B. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47, 507–514. [CrossRef] [PubMed]
3. Ahmadian, M.; Suh, J.M.; Hah, N.; Liddle, C.; Atkins, A.R.; Downes, M.; Evans, R.M. PPARγ signaling and metabolism: The good, the bad and the future. Nat. Med. 2013, 99, 557–566. [CrossRef] [PubMed]
4. Fuentes, L.; Roszer, T.; Ricote, M. Inflammatory mediators and insulin resistance in obesity: Role of nuclear receptor signaling in macrophages. Mediat. Inflamm. 2010. [CrossRef] [PubMed]
5. Blanquart, C.; Barbier, O.; Fruchart, J.C.; Staels, B.; Glineur, C. Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. 2003, 85, 267–273. [CrossRef]
6. Jiang, C.; Ting, A.T.; Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391, 82–86. [CrossRef] [PubMed]
7. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391, 79–82. [CrossRef] [PubMed]
8. Bo, Q.-L.; Chen, Y.-H.; Yu, Z.; Fu, L.; Zhou, Y.; Zhang, G.-B.; Wang, H.; Zhang, Z.-H.; Xu, D.-X. Rosiglitazone pretreatment protects against lipopolysaccharide-induced fetal demise through inhibiting placental inflammation. Mol. Cell. Endocrinol. 2016, 423, 51–59. [CrossRef] [PubMed]
9. Lee, S.; Kim, W.; Kang, K.P.; Moon, S.-O.; Sung, M.J.; Kim, D.H.; Kim, H.J.; Park, S.K. Agonist of peroxisome proliferator-activated receptor-γ, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol. Dial. Transplant. 2005, 20, 1057–1065. [CrossRef] [PubMed]
10. Cuzzocrea, S.; Pisano, B.; Dugo, L.; Iannolo, A.; Maffia, P.; Patel, N.S.; Di Paola, R.; Ialenti, A.; Genovese, T.; Chatterjee, P.K. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur. J. Pharmacol. 2004, 483, 79–93. [CrossRef] [PubMed]
11. Ward, J.; Fernandes, D.; Taylor, C.; Bonacci, J.; Quan, L.; Stewart, A. The PPARγ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulm. Pharmacol. Ther. 2006, 19, 39–46. [CrossRef] [PubMed]
12. Birrell, M.; Patel, H.; McCluskie, K.; Wong, S.; Leonard, T.; Yacoub, M.; Belvisi, M. PPAR-γ agonists as therapy for diseases involving airway neutrophilia. Eur. Respir. J. 2004, 24, 267–273. [CrossRef] [PubMed]
13. Hasegawa, H.; Takano, H.; Zou, Y.; Qin, Y.; Hizukuri, K.; Odaka, K.; Toyozaki, T.; Komuro, I. Rosiglitazone, a peroxisome proliferator-activated receptor γ activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J. Mol. Cell. Cardiol. 2005, 38, 257–265. [CrossRef] [PubMed]
14. Ramakers, J.D.; Verstege, M.I.; Thuijls, G.; Te Velde, A.A.; Mensink, R.P.; Plat, J. The PPARγ agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J. Clin. Immunol. 2007, 27, 275–283. [CrossRef] [PubMed]
15. Yamagishi, S.-I.; Matsui, T.; Nakamura, K.; Takeuchi, M.; Inoue, H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-γ activation. Protein Pept. Lett. 2008, 15, 850–853. [CrossRef] [PubMed]
16. Di, B.B.; Li, H.W.; Li, W.P.; Shen, X.H.; Sun, Z.J.; Wu, X. Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells. Mol. Med. Rep. 2015, 11, 2601–2607. [CrossRef] [PubMed]
17. Dang, H.T.; Lee, H.J.; Yoo, E.S.; Hong, J.; Bao, B.; Choi, J.S.; Jung, J.H. New jasmonate analogues as potential anti-inflammatory agents. Bioorg. Med. Chem. 2008, 16, 10228–10235. [CrossRef] [PubMed]
18. Choo, J.; Lee, Y.; Yan, X.-J.; Noh, T.H.; Kim, S.J.; Son, S.; Pothoulakis, C.; Moon, H.R.; Jung, J.H.; Im, E. A novel peroxisome proliferator-activated receptor (PPAR) \( \gamma \) agonist 2-hydroxyethyl 5-chloro-4, 5-didehydrojasmonate exerts anti-inflammatory effects in colitis. *J. Biol. Chem.* **2015**, *290*, 25609–25619. [CrossRef] [PubMed]

19. Liu, J.; Li, F.; Kim, E.L.; Li, J.L.; Hong, J.; Bae, K.S.; Chung, H.Y.; Kim, H.S.; Jung, J.H. Antibacterial polyketides from the jellyfish-derived fungus *Paecilomyces variotii*. *J. Nat. Prod.* **2011**, *74*, 1826–1829. [CrossRef] [PubMed]

20. Xiao, B.; Yin, J.; Park, M.; Liu, J.; Li, J.L.; La Kim, E.; Hong, J.; Chung, H.Y.; Jung, J.H. Design and synthesis of marine fungal phthalide derivatives as PPAR-\( \gamma \) agonists. *Bioorg. Med. Chem.* **2012**, *20*, 4954–4961. [CrossRef] [PubMed]

21. Xiao, B.; Su, M.; Kim, E.L.; Hong, J.; Chung, H.Y.; Kim, H.S.; Yin, J.; Jung, J.H. Synthesis of PPAR-\( \gamma \) activators inspired by the marine natural product, paecilocin A. *Bioorg. Med. Chem.* **2014**, *12*, 926–939. [CrossRef] [PubMed]

22. Eom, S.H.; Liu, S.; Su, M.; Noh, T.H.; Hong, J.; Kim, N.D.; Chung, H.Y.; Yang, M.H.; Jung, J.H. Synthesis of phthalimide derivatives as potential PPAR-\( \gamma \) ligands. *Mar. Drugs* **2016**, *14*, 112. [CrossRef] [PubMed]

23. Szanto, A.; Nagy, L. The many faces of PPAR\( \gamma \): Anti-inflammatory by any means? *Immunobiology* **2008**, *213*, 789–803. [CrossRef] [PubMed]

24. Ando, Y.; Oku, T.; Tsuji, T. Platelet supernatant suppresses LPS-induced nitric oxide production from macrophages accompanied by inhibition of NF-\( \kappa \)B signaling and increased arginase-1 expression. *PLoS ONE* **2016**, *11*, e0162208. [CrossRef] [PubMed]

25. Gao, S.; Zhou, J.; Liu, N.; Wang, L.; Gao, Q.; Wu, Y.; Zhao, Q.; Liu, P.; Wang, S.; Liu, Y. Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13. *J. Mol. Cell. Cardiol.* **2015**, *85*, 131–139. [CrossRef] [PubMed]

26. Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O’Garra, A. Interleukin-10 and the interleukin-10 receptor. *Annu. Rev. Immunol.* **2001**, *19*, 683–765. [CrossRef] [PubMed]

27. Csuka, E.; Morganti-Kossmann, M.C.; Lenzlinger, P.M.; Joller, H.; Trentz, O.; Kossmann, T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-\( \alpha \), TGF-\( \beta \)1 and blood–brain barrier function. *J. Neuroimmunol.* **1999**, *101*, 211–221. [CrossRef]

28. Niiro, H.; Otsuka, T.; Kuga, S.; Nemoto, Y.; Abe, M.; Hara, N.; Nakano, T.; Ogo, T.; Niho, Y. IL-10 inhibits prostaglandin E2 production by lipopolysaccharide-stimulated monocytes. *Int. Immunol.* **1994**, *6*, 661–664. [CrossRef] [PubMed]

29. Yang, S.-L.; Chen, S.-L.; Wu, J.-Y.; Ho, T.-C.; Tsao, Y.-P. Pigment epithelium-derived factor induces interleukin-10 expression in human macrophages by induction of PPAR gamma. *Life Sci.* **2010**, *87*, 26–35. [CrossRef] [PubMed]

30. Kim, S.R.; Lee, K.S.; Park, H.S.; Park, S.J.; Min, K.H.; Jin, S.M.; Lee, Y.C. Involvement of IL-10 in peroxisome proliferator-activated receptor \( \gamma \)-mediated anti-inflammatory response in asthma. *Mol. Pharmacol.* **2005**, *68*, 1568–1575. [PubMed]

31. Dang, H.T.; Lee, Y.M.; Kang, G.J.; Yoo, E.S.; Hong, J.; Lee, S.M.; Lee, S.K.; Pyee, Y.; Chung, H.-J.; Moon, H.R. In vitro stability and in vivo anti-inflammatory efficacy of synthetic jasmonates. *Bioorg. Med. Chem.* **2012**, *20*, 4109–4116. [CrossRef] [PubMed]

32. Da Silva Lima, M.; Quintans-Junior, L.J.; de Santana, W.A.; Kaneto, C.M.; Soares, M.B.P.; Villarreal, C.F. Anti-inflammatory effects of carvacrol: Evidence for a key role of interleukin-10. *Eur. J. Pharmacol.* **2013**, *699*, 112–117. [CrossRef] [PubMed]

33. Park, S.-J.; Lee, K.-P.; Kang, S.; Lee, J.; Sato, K.; Chung, H.Y.; Okajima, F.; Im, D.-S. Sphingosine 1-phosphate induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. *Cell. Signal.* **2014**, *26*, 2249–2258. [CrossRef] [PubMed]